FDA Approves AVERT-D: The Genetic Test to Assess Risk of Opioid Use Disorder
In a groundbreaking move, the FDA has granted its approval for the use of AVERT-D, the first-ever genetic test designed to identify individuals with an increased risk of developing opioid use disorder. The test utilizes DNA analysis to assess an individual's susceptibility to this debilitating condition, aiming to provide valuable insights for healthcare providers. While some remain skeptical of its effectiveness, AVERT-D is being hailed as a crucial tool in the ongoing battle against the destructive opioid epidemic.
